Corinfar user manual
You can buy Corinfar on this page
Corinfar is a selective calcium channel blocker with antianginal and hypotensive effects.
Release form and composition
Dosage form - tablets of prolonged action, film-coated: round biconvex shape with beveled edges, homogeneous core structure and film shell are yellow (10 pcs. In blisters, in a cardboard box 3 blisters; 50 or 100 pcs. In glass brown bottles, in a cardboard box 1 bottle).
The active ingredient is nifedipine, in 1 tablet - 10 mg.
Auxiliary components: potato starch, lactose monohydrate, microcrystalline cellulose, magnesium stearate, povidone K25.
The composition of the film shell: macrogol 6000, hypromellose, macrogol 35,000, titanium dioxide (E171), quinoline yellow dye (E104), talc.
Indications for use
The use of Corinfar is indicated for the treatment of cardiovascular diseases:
Chronic stable angina pectoris or exertional angina;
Variant angina (Prinzmetal's angina).
Chronic heart failure in the stage of decompensation;
Arterial hypotension (with systolic blood pressure (BP) below 90 mm Hg);
Severe aortic stenosis;
Cardiogenic shock, collapse;
Concomitant use with rifampicin;
Acute myocardial infarction (first 4 weeks);
I trimester of pregnancy;
Hypersensitivity to the components of Corinfar and other derivatives of 1,4-dihydropyridine.
It is recommended to prescribe the drug with caution to patients with hypertrophic obstructive cardiomyopathy, mitral stenosis, severe tachycardia or bradycardia, malignant arterial hypertension, sick sinus syndrome (SSSS), hypovolemia, myocardial infarction with left ventricular failure, severe gastrointestinal circulatory disorders, cerebrovascular accident (Gastrointestinal tract), hepatic and renal failure, hemodialysis, in combination with beta-blockers and digoxin, as well as in the II and III trimesters of pregnancy; under the age of 18.
Method of administration and dosage
The tablets are taken orally, without chewing, after meals, with a small amount of liquid. Simultaneous food intake does not reduce the absorption of nifedipine from the gastrointestinal tract, but delays it.
The doctor prescribes the dose of Corinfar and the period of treatment based on clinical indications, taking into account the severity of the disease and the patient's individual sensitivity to the drug.
Arterial (essential) hypertension: initial dose - 1 tablet 2-3 times a day, to achieve a pronounced clinical effect, the dose can be gradually increased to the maximum daily dose - 2 tablets 2 times a day;
Chronic vasospastic and stable angina pectoris: the initial dose is 1 tablet 2-3 times a day, to achieve a pronounced therapeutic effect, a single dose is gradually increased to 2 tablets with a frequency of administration 1-2 times a day. The daily dose should not exceed 4 tablets.
With a frequency of administration 2 times a day, a break between doses of at least 4 hours should be observed.
When prescribing Corinfar to patients with concomitant severe cerebrovascular pathologies and elderly patients, the dose should be reduced.
From the hematopoietic system: leukopenia, anemia, thrombocytopenia, agranulocytosis, thrombocytopenic purpura;
From the side of the cardiovascular system: palpitations, tachycardia, arrhythmias, manifestations of excessive vasodilation (decrease in blood pressure (asymptomatic), worsening or development of heart failure, feeling of heat, flushing of the facial skin, flushing of the skin of the face), peripheral edema (feet, ankles , shins), syncope; rarely - a pronounced decrease in blood pressure; in isolated cases - attacks of angina pectoris, the development of myocardial infarction (more often at the beginning of treatment or when the dose is increased);
From the digestive system: dry mouth, dyspepsia (nausea, constipation or diarrhea), increased appetite, flatulence; rarely - transient gingival hyperplasia; with prolonged use - liver dysfunction in the form of intrahepatic cholestasis, increased activity of liver enzymes;
From the nervous system: general weakness, headache, drowsiness, dizziness, fatigue; with prolonged use in high doses - tremor, paresthesia of the extremities, parkinsonian (extrapyramidal) disorders (difficulty swallowing, mask-like face, ataxia, shuffling gait, tremor of fingers and hands), depression;
From the musculoskeletal system: myalgia, arthritis, cramps of the lower and upper extremities, swelling of the joints;
From the urinary system: with renal failure - deterioration of renal function, increased daily urine output;
Allergic reactions: rarely - photodermatosis, pruritus, exanthema, urticaria, exfoliative dermatitis, autoimmune hepatitis, anaphylactic reactions;
Others: rarely - galactorrhea, bronchospasm, pulmonary edema, hyperglycemia, weight gain, visual impairment, including transient blindness against the background of maximum plasma concentration of nifedipine; in elderly patients - gynecomastia (disappears after discontinuation of Corinfar).
You can not drink alcoholic beverages during the treatment period.
Cancellation of the drug must be carried out by gradually reducing the dose.
It should be borne in mind that at the beginning of the use of Corinfar, especially against the background of a sharp recent withdrawal of beta-blockers, angina pectoris may appear.
Combined use with beta-blockers can cause a strong decrease in blood pressure, and sometimes an exacerbation of symptoms of heart failure, so it is recommended to be accompanied by careful medical supervision.
Patients with severe heart failure should be prescribed the dose of Corinfar with great caution.
Patients with severe obstructive cardiomyopathy while taking nifedipine are at risk of increasing the frequency, duration of attacks and the severity of angina pectoris; in this case, there may be a question of discontinuing the drug.
Patients with impaired renal function should be treated under close regular monitoring, and, if necessary, with a decrease in the dose of nifedipine. Due to the high risk of a sharp drop in blood pressure, Corinfar should be used with caution in patients with high blood pressure and reduced circulating blood volume against the background of concomitant irreversible renal failure on hemodialysis.
With vasospastic angina, it is necessary to be guided by the main criteria for the appointment of Corinfar: the classic clinic of the disease with an increase in the ST segment, the appearance of spasm of the coronary arteries or ergonovine-induced angina pectoris, detection of coronary spasm or an angiospastic component during angiography without confirmation.
Before surgery using general anesthesia, it is necessary to inform the anesthesiologist about taking the drug.
In some cases, Corinfar can cause changes in the head of the sperm (possibly dysfunction of the sperm, should be taken into account in in vitro fertilization).
When conducting laboratory tests for the detection of antinuclear antibodies and a direct Coombs' reaction while taking nifedipine, it is possible to obtain a false positive result.
The combination of nifedipine with disopyramide and flecainamide can lead to an increase in the inotropic effect, therefore, if necessary, this combination should be treated with caution.
Against the background of taking the drug, the spectrophotometric determination in the urine of the content of vanillyl mandelic acid gives an overestimated result.
During the period of use of Corinfar, patients are advised to be careful when driving vehicles and mechanisms, as well as when engaging in those activities, the implementation of which requires increased attention and high speed of psychomotor reactions.
It is not recommended to prescribe the drug in conjunction with rifampicin, since it accelerates the metabolism of nifedipine.
The antihypertensive effect of nifedipine can be enhanced by the simultaneous use of other antihypertensive drugs, tricyclic antidepressants, cimetidine, nitrates, diuretics, inhalation anesthetics, alpha-blockers (prazosin).
The drug is able to enhance the negative inotropic effect of amiodarone and quinidine and reduce the concentration of quinidine in the blood plasma.
With the simultaneous use of Corinfar:
Nitrates - increase tachycardia;
Diltiazem, grapefruit juice - inhibits the metabolism of nifedipine in the body;
Theophylline, digoxin, cephalosporins - increase the level of their concentration in the blood plasma;
Non-steroidal anti-inflammatory drugs (NSAIDs) (against the background of suppression of prostaglandin synthesis in the kidneys and retention of fluid and sodium ions in the body), sympathomimetics, estrogens - reduce the hypotensive effect of Corinfar;
Quinidine, procainamide and other drugs that prolong the QT interval - cause a significant lengthening of the QT interval;
Lithium preparations can increase the toxic effect (nausea, tinnitus, vomiting, diarrhea, tremor, ataxia);
Antiviral drugs (including indinavir, amprenavir, nelfinavir, saquinavir, ritonavir), macrolides, antifungal agents of the azole group (fluconazole, ketoconazole or itraconazole), valproic acid - cause an increase in the concentration of the drug in the blood plasma;
Carbamazepine and phenobarbital can reduce the content of nifedipine in blood plasma.
When combined with indirect anticoagulants (derivatives of indandione and coumarin, anticonvulsants, quinine, NSAIDs, sulfinpyrazone, salicylates) and other agents with a high degree of binding to plasma proteins, the action of Corinfar can cause an increase in their level in blood plasma.
If necessary, the simultaneous administration of the dose of vincristine should be reduced, since this combination can lead to increased side effects.
Terms and conditions of storage
Store in a dark place at temperatures up to 25 ° C. Keep out of the reach of children.
The shelf life is 5 years.
Terms of sell
You don't need a prescription to buy Corinfar.